Click here for slides on this topic


Glucagon

A hormone produced in the pancreas that signals the liver to release stored sugar into the bloodstream. Glucagon is often oversecreted in patients with type 2 diabetes, especially at mealtime.


The following content matched the glossary term: Glucagon

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 8, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 8, 2012

Diabetes and hypoglycemia, clinical management of diabetes, obesity treatment, diabetes in long-term care, and more. 

Effects of glucagon-like peptide-1 receptor agonists on weight loss

Top

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj.d7771. Vilsbøll and colleagues conducted a meta-analysis and systematic review of trials to analyze the risks and benefits of GLP-1 receptor agonists among overweight or obese subjects with type 2 diabetes.

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment

Top

Nowicki M, Rychlik I, Haller H, et al. Int J Clin Pract . Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. 2011;65(12):1230-1239. Nowicki and colleagues examined the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor, saxagliptin, among patients with inadequately controlled type 2 diabetes and renal impairment in a 52-week study.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

Top

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting systematic review and meta analysis. BMJ. 2012;344:e1369. doi 10.1136 bmj.e1369. OBJECTIVE: To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors compared with metformin as monotherapy, or with other commonly used hypoglycaemic drugs combined with metformin, in adults with type 2 diabetes mellitus.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults

Top

Tzefos M, Harris K, Brackett A. Clinical efficacy and safety of once weekly glucagon like peptide 1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother. 2012;46(1):68-78. OBJECTIVE: To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM).

Proportion of patients at HbA1c target greater than 7% with eight classes of antidiabetic drugs in type 2 diabetes

Top

Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients. Diabetes Obes Metab. 2011 Sep 29. doi: 10.1111/j.1463-1326.2011.01512.x. [Epub ahead of print]. We assessed the efficacy of eight classes of diabetes medications used in current clinical practice [metformin, sulphonylureas, α-glucosidase inhibitors, thiazolidinediones, glinides, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 (GLP-1) analogues and insulin analogues] to reach the HbA1c target <7% in type 2 diabetes.

Glucagon-like peptide analogues for type 2 diabetes mellitus

Top

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD006423. Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes that mimic the endogenous hormone glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in response to ingested nutrients.

Evaluating the long-term cost-effectiveness of liraglutide vs exenatide BID in patients w/ type 2 diabetes who fail to improve w/ oral antidiabetic agents

Top

Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011 Oct 19. [Epub ahead of print] The global clinical and economic burden of type 2 diabetes is substantial. Recently, clinical trials with glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide and exenatide) have shown a multifactorial clinical profile with the potential to address many of the clinical needs of patients and reduce the burden of disease.

Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction

Top

Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes. 2011 Oct 17. [Epub ahead of print] AIMS: To evaluate the effects of adding glucagon-like peptide-1 (GLP-1) analogue therapy to insulin on glycated hemoglobin (HbA1c), weight, insulin dosage, treatment satisfaction, and risk of hypoglycaemia.

1 2 3 4 5 6 7 Next 

Slide Library Results

Search Results for: Glucagon Slides Found: 71
Exenatide: Clinical Pharmacology
Pramlintide Adjunctive Therapy Offers Long-Term Glycemic Control
Effect of Pramlintide Adjunctive Therapy on Weight in Patients With Type 2 Diabetes
Glucagon-Like Peptide-1
Insulin and GLP-1 Responses to Meals
GLP-1 Release Is Reduced in Type 2 Diabetes
Effect of GLP-1 on the Beta-Cell
GLP-1 Infusion Improves Beta-Cell Insulin Secretion
GLP-1 and First-Phase Insulin Secretion
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
Plasticity of Islets: Experimental Increase in Beta-Cell Mass in Response to IR
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: A1C
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: Body Weight
Once-Weekly Exenatide LAR vs Twice-Daily Exenatide for Type 2 Diabetes: A1C Categories
Vildagliptin vs Metformin: A1C
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Results
Effect of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Design
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Results
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Additional Results
DURATION-6: Design
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Results for Glucose and Hormones
ADA/Endocrine Society: Classification of Hypoglycemia in Diabetes
GLP-1 Receptor Agonists: Dosage Adjustment by Degree of Renal Impairment
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
EXAMINE: Adverse Events
EXAMINE: Design
ADA Nutrition Guidelines: Priorities for Nutrition Management By Medication
Liraglutide 12-Week Treatment: Effect on Glycemic Control
LEAD-3: Liraglutide vs Glimepiride: A1C Level
LEAD-3: Liraglutide vs Glimepiride in Drug-Naïve Patients: A1C
LEAD-3: Liraglutide vs Glimepiride in Previously on Oral Agents: A1
Liraglutide Improves ß-Cell Function and Insulin Secretion During Hyperglycemia in Patients With Type 2 Diabetes
Liraglutide Enhances Glucose-Dependent Insulin Secretion
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Treatment Management | NDEI
IDF Type 2 Diabetes Treatment Guidelines Older Adults Elderly | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
A1C Reduction GLP-1 RAs & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Similar A1C Goal Achievement GLP-1 RA & Glargine DURATION-3 & LEAD-5 | NDEI
Weight Loss With GLP-1 RA & Increase With Glargine in DURATION-3 & LEAD-5 | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Combination GLP-1 RA & Basal Insulin Treatment Type 2 Diabetes | NDEI
Hypoglycemia & Weight After Treatment With GLP-1 RA + Basal Insulin | NDEI
AACE 2015 Diabetes Guidelines Hypoglycemia Management PPT | NDEI
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
ADA Diabetes Guidelines Pharmacologic Therapy for Older Adults | NDEI